Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 and 2 Study of 5-aminolevulinic Acid (5-ALA) to Enhance Visualisation and Resection of Malignant Glial Tumors of the Brain

NCT01128218 is registered in ClinicalTrials.gov with Southern Illinois University as lead sponsor.

NCT NCT01128218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01128218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 and 2 Study of 5-aminolevulinic Acid (5-ALA) to Enhance Visualisation and Resection of Malignant Glial Tumors of the Brain
Lead sponsor
Southern Illinois University
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2011
Completion date
February 28, 2021
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms